Concerning RNA interference (RNAi) therapies, as the one here proposed, 2018 marked the first approval of an RNAi drug in the USA, patisiran, for the treatment of the polyneuropathy of hereditary TTR-mediated amyloidosis, and since then, several drugs have been approved in the USA and Europe and many more are in late phase 3 clinical trials [39,40]. Here, TTR is linked to polyneuropathy.